| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Mullerian Hormone | 7 | 2020 | 37 | 4.220 |
Why?
|
| Ovary | 10 | 2021 | 389 | 4.000 |
Why?
|
| Ovulation Induction | 7 | 2024 | 60 | 2.860 |
Why?
|
| Uterus | 8 | 2024 | 594 | 2.470 |
Why?
|
| Pregnancy Trimester, First | 7 | 2024 | 111 | 2.150 |
Why?
|
| Ultrasonography | 10 | 2024 | 945 | 2.090 |
Why?
|
| Gonadotropin-Releasing Hormone | 7 | 2013 | 88 | 2.030 |
Why?
|
| Urogenital Abnormalities | 4 | 2021 | 168 | 1.940 |
Why?
|
| Fertilization in Vitro | 5 | 2024 | 188 | 1.910 |
Why?
|
| Ultrasonography, Prenatal | 12 | 2024 | 906 | 1.860 |
Why?
|
| Endometrium | 7 | 2021 | 276 | 1.730 |
Why?
|
| Abortion, Spontaneous | 4 | 2021 | 85 | 1.640 |
Why?
|
| Fertility Preservation | 3 | 2021 | 61 | 1.510 |
Why?
|
| Hysteroscopy | 4 | 2021 | 38 | 1.480 |
Why?
|
| Polyps | 2 | 2021 | 48 | 1.470 |
Why?
|
| Yolk Sac | 2 | 2020 | 22 | 1.360 |
Why?
|
| Polycystic Ovary Syndrome | 4 | 2020 | 58 | 1.320 |
Why?
|
| Pregnancy | 38 | 2024 | 7115 | 1.210 |
Why?
|
| Cyclophosphamide | 4 | 2014 | 420 | 1.200 |
Why?
|
| Infertility, Female | 5 | 2015 | 165 | 1.200 |
Why?
|
| Reproductive Techniques, Assisted | 3 | 2013 | 78 | 1.140 |
Why?
|
| Oocytes | 5 | 2023 | 290 | 1.080 |
Why?
|
| Pregnancy Outcome | 9 | 2020 | 595 | 1.020 |
Why?
|
| Ultrasonography, Doppler | 8 | 2006 | 197 | 0.950 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2014 | 99 | 0.930 |
Why?
|
| Sexual Maturation | 2 | 2013 | 48 | 0.880 |
Why?
|
| Female | 61 | 2024 | 65310 | 0.880 |
Why?
|
| Fertility Agents, Female | 3 | 2017 | 9 | 0.880 |
Why?
|
| Fetus | 5 | 2018 | 570 | 0.880 |
Why?
|
| Ovarian Follicle | 2 | 2018 | 119 | 0.850 |
Why?
|
| Follicle Stimulating Hormone | 4 | 2018 | 186 | 0.830 |
Why?
|
| Sodium Chloride | 1 | 2021 | 97 | 0.760 |
Why?
|
| Receptors, Peptide | 2 | 2020 | 47 | 0.760 |
Why?
|
| Estradiol | 4 | 2018 | 534 | 0.760 |
Why?
|
| Insulins | 1 | 2021 | 17 | 0.750 |
Why?
|
| Reproduction | 2 | 2013 | 242 | 0.740 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2020 | 107 | 0.730 |
Why?
|
| Pregnancy Complications | 5 | 2020 | 505 | 0.720 |
Why?
|
| Genes, BRCA2 | 1 | 2020 | 42 | 0.720 |
Why?
|
| Genes, BRCA1 | 1 | 2020 | 51 | 0.710 |
Why?
|
| Gestational Sac | 1 | 2020 | 2 | 0.700 |
Why?
|
| Fallopian Tubes | 1 | 2020 | 72 | 0.690 |
Why?
|
| Sperm Injections, Intracytoplasmic | 3 | 2008 | 34 | 0.680 |
Why?
|
| Granulosa Cells | 1 | 2020 | 133 | 0.670 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 1390 | 0.660 |
Why?
|
| RNA, Messenger | 4 | 2020 | 2820 | 0.650 |
Why?
|
| Primary Ovarian Insufficiency | 3 | 2014 | 42 | 0.650 |
Why?
|
| Cell Dedifferentiation | 1 | 2019 | 21 | 0.650 |
Why?
|
| Adult | 28 | 2024 | 28980 | 0.630 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 1675 | 0.630 |
Why?
|
| Pilot Projects | 5 | 2021 | 1386 | 0.620 |
Why?
|
| Receptors, Pituitary Hormone | 1 | 2017 | 2 | 0.600 |
Why?
|
| Apoptosis | 3 | 2020 | 1783 | 0.600 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2017 | 359 | 0.600 |
Why?
|
| Heterografts | 1 | 2018 | 179 | 0.590 |
Why?
|
| Hormone Antagonists | 2 | 2008 | 63 | 0.590 |
Why?
|
| Blood Flow Velocity | 9 | 2006 | 447 | 0.590 |
Why?
|
| Humans | 59 | 2024 | 122998 | 0.580 |
Why?
|
| Logistic Models | 2 | 2020 | 1796 | 0.570 |
Why?
|
| Erythroblastosis, Fetal | 5 | 2003 | 27 | 0.570 |
Why?
|
| Mullerian Ducts | 1 | 2017 | 40 | 0.550 |
Why?
|
| Pregnancy, Multiple | 2 | 2019 | 50 | 0.530 |
Why?
|
| Down-Regulation | 3 | 2008 | 697 | 0.530 |
Why?
|
| Gene Expression Regulation | 3 | 2020 | 2533 | 0.500 |
Why?
|
| Middle Cerebral Artery | 5 | 2003 | 110 | 0.500 |
Why?
|
| Placenta | 1 | 2019 | 493 | 0.480 |
Why?
|
| Goserelin | 1 | 2014 | 4 | 0.460 |
Why?
|
| Prospective Studies | 9 | 2020 | 6023 | 0.460 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 130 | 0.460 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2013 | 42 | 0.440 |
Why?
|
| Receptors, Progesterone | 3 | 2021 | 865 | 0.440 |
Why?
|
| Neoplasms | 2 | 2021 | 2750 | 0.440 |
Why?
|
| Cohort Studies | 7 | 2024 | 4705 | 0.430 |
Why?
|
| Cell Proliferation | 1 | 2020 | 2306 | 0.420 |
Why?
|
| Receptors, Prolactin | 2 | 2013 | 11 | 0.420 |
Why?
|
| Anemia | 5 | 2002 | 339 | 0.410 |
Why?
|
| Pregnancy Reduction, Multifetal | 1 | 2011 | 21 | 0.380 |
Why?
|
| Receptors, Estrogen | 2 | 2021 | 789 | 0.380 |
Why?
|
| Ovarian Cysts | 1 | 2011 | 24 | 0.380 |
Why?
|
| Infertility | 2 | 2008 | 90 | 0.330 |
Why?
|
| Receptors, FSH | 2 | 2020 | 16 | 0.330 |
Why?
|
| Vitrification | 2 | 2019 | 5 | 0.320 |
Why?
|
| Inhibins | 2 | 2020 | 87 | 0.320 |
Why?
|
| Metrorrhagia | 1 | 2008 | 7 | 0.310 |
Why?
|
| Retrospective Studies | 12 | 2024 | 15931 | 0.310 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 407 | 0.310 |
Why?
|
| Peritoneum | 1 | 2008 | 36 | 0.310 |
Why?
|
| Biomarkers | 2 | 2015 | 2940 | 0.300 |
Why?
|
| Embryo Transfer | 2 | 2024 | 82 | 0.290 |
Why?
|
| Sensitivity and Specificity | 4 | 2021 | 2021 | 0.290 |
Why?
|
| Pregnancy, Ectopic | 2 | 2024 | 29 | 0.290 |
Why?
|
| Cryopreservation | 2 | 2021 | 82 | 0.290 |
Why?
|
| Chorionic Gonadotropin | 1 | 2007 | 83 | 0.280 |
Why?
|
| Ovulation | 1 | 2007 | 113 | 0.270 |
Why?
|
| Fetal Diseases | 4 | 2002 | 440 | 0.260 |
Why?
|
| Terminology as Topic | 2 | 2024 | 229 | 0.260 |
Why?
|
| Organ Size | 2 | 2020 | 412 | 0.260 |
Why?
|
| Mice | 7 | 2023 | 17469 | 0.250 |
Why?
|
| Fertility | 2 | 2021 | 263 | 0.250 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 91 | 0.250 |
Why?
|
| HELLP Syndrome | 1 | 2005 | 19 | 0.250 |
Why?
|
| Receptors, Androgen | 1 | 2008 | 409 | 0.240 |
Why?
|
| Puerperal Disorders | 1 | 2005 | 46 | 0.240 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2005 | 67 | 0.240 |
Why?
|
| Blood Transfusion, Intrauterine | 2 | 2002 | 37 | 0.240 |
Why?
|
| Mice, Inbred C57BL | 4 | 2014 | 4342 | 0.230 |
Why?
|
| Fetal Blood | 4 | 2020 | 177 | 0.230 |
Why?
|
| Mesenteric Artery, Superior | 2 | 2001 | 35 | 0.220 |
Why?
|
| Fibroblasts | 1 | 2008 | 877 | 0.220 |
Why?
|
| Aminopyridines | 1 | 2024 | 53 | 0.220 |
Why?
|
| Heparin | 1 | 2005 | 229 | 0.220 |
Why?
|
| Pregnancy Rate | 2 | 2017 | 48 | 0.220 |
Why?
|
| Gestational Age | 11 | 2005 | 1116 | 0.220 |
Why?
|
| Pregnancy Proteins | 1 | 2023 | 13 | 0.210 |
Why?
|
| Reference Values | 3 | 2019 | 696 | 0.210 |
Why?
|
| Karyopherins | 1 | 2023 | 35 | 0.210 |
Why?
|
| Pyrroles | 1 | 2024 | 177 | 0.200 |
Why?
|
| Ultrasonography, Doppler, Color | 2 | 2001 | 57 | 0.200 |
Why?
|
| Animals | 7 | 2023 | 33693 | 0.190 |
Why?
|
| Ki-67 Antigen | 1 | 2021 | 113 | 0.190 |
Why?
|
| Fetal Growth Retardation | 4 | 2006 | 222 | 0.180 |
Why?
|
| Endometriosis | 1 | 2024 | 185 | 0.180 |
Why?
|
| Body Mass Index | 1 | 2007 | 1542 | 0.180 |
Why?
|
| Peritoneal Cavity | 1 | 2020 | 18 | 0.180 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2001 | 97 | 0.180 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 3359 | 0.180 |
Why?
|
| Young Adult | 5 | 2020 | 8840 | 0.180 |
Why?
|
| Oocyte Retrieval | 1 | 2020 | 6 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 172 | 0.180 |
Why?
|
| Follicular Fluid | 1 | 2020 | 8 | 0.180 |
Why?
|
| Suction | 1 | 2020 | 57 | 0.180 |
Why?
|
| Pressure | 1 | 2020 | 130 | 0.180 |
Why?
|
| Caspase 3 | 1 | 2020 | 131 | 0.170 |
Why?
|
| Anticoagulants | 1 | 2005 | 585 | 0.170 |
Why?
|
| Nomograms | 1 | 2019 | 36 | 0.170 |
Why?
|
| Mice, Nude | 1 | 2020 | 691 | 0.160 |
Why?
|
| Hot Temperature | 1 | 2019 | 135 | 0.160 |
Why?
|
| Nanog Homeobox Protein | 1 | 2018 | 27 | 0.150 |
Why?
|
| Analysis of Variance | 1 | 2020 | 1011 | 0.150 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2018 | 42 | 0.150 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2018 | 57 | 0.150 |
Why?
|
| Counseling | 1 | 2020 | 219 | 0.150 |
Why?
|
| Receptors, LH | 1 | 2017 | 13 | 0.150 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 25 | 0.150 |
Why?
|
| Ovariectomy | 1 | 2018 | 181 | 0.150 |
Why?
|
| Vaccination | 1 | 2023 | 949 | 0.150 |
Why?
|
| Clomiphene | 1 | 2017 | 11 | 0.150 |
Why?
|
| Premenopause | 1 | 2017 | 31 | 0.150 |
Why?
|
| Transplantation, Heterologous | 1 | 2018 | 254 | 0.150 |
Why?
|
| Risk Factors | 4 | 2015 | 9974 | 0.140 |
Why?
|
| Genitalia, Female | 1 | 2017 | 48 | 0.140 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2001 | 383 | 0.130 |
Why?
|
| Biopsy | 2 | 2011 | 1239 | 0.130 |
Why?
|
| Blood Glucose | 1 | 2020 | 1113 | 0.130 |
Why?
|
| Prognosis | 3 | 2020 | 4490 | 0.120 |
Why?
|
| Glucose Intolerance | 1 | 2015 | 75 | 0.120 |
Why?
|
| ROC Curve | 2 | 2015 | 556 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2020 | 501 | 0.120 |
Why?
|
| Insulin Resistance | 1 | 2020 | 638 | 0.120 |
Why?
|
| Regional Blood Flow | 2 | 2006 | 210 | 0.110 |
Why?
|
| Testosterone | 1 | 2018 | 462 | 0.110 |
Why?
|
| Bone Development | 1 | 2014 | 56 | 0.110 |
Why?
|
| Adolescent | 3 | 2020 | 19030 | 0.110 |
Why?
|
| Receptors, Thyrotropin | 1 | 2013 | 11 | 0.110 |
Why?
|
| Incidence | 1 | 2021 | 3047 | 0.110 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2018 | 996 | 0.110 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2013 | 123 | 0.110 |
Why?
|
| Puberty | 1 | 2014 | 94 | 0.110 |
Why?
|
| Prolactin | 1 | 2013 | 103 | 0.110 |
Why?
|
| Fetofetal Transfusion | 3 | 2001 | 191 | 0.110 |
Why?
|
| Sexual Development | 1 | 2013 | 23 | 0.110 |
Why?
|
| Drug Interactions | 1 | 2014 | 252 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 2837 | 0.110 |
Why?
|
| Femur | 1 | 2013 | 63 | 0.100 |
Why?
|
| Hormones | 1 | 2013 | 190 | 0.100 |
Why?
|
| Organ Preservation | 1 | 2012 | 36 | 0.100 |
Why?
|
| Triplets | 1 | 2011 | 11 | 0.100 |
Why?
|
| Transplantation, Autologous | 1 | 2012 | 295 | 0.100 |
Why?
|
| Luteal Cells | 1 | 2011 | 9 | 0.100 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 2 | 2002 | 25 | 0.090 |
Why?
|
| Oocyte Donation | 1 | 2011 | 39 | 0.090 |
Why?
|
| Estrogen Receptor beta | 1 | 2011 | 78 | 0.090 |
Why?
|
| Societies, Medical | 2 | 2024 | 678 | 0.090 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 384 | 0.090 |
Why?
|
| Amniotic Fluid | 3 | 2001 | 151 | 0.090 |
Why?
|
| Systole | 4 | 2002 | 198 | 0.080 |
Why?
|
| Fertility Agents | 1 | 2008 | 1 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 1684 | 0.080 |
Why?
|
| Peritoneal Diseases | 1 | 2008 | 9 | 0.080 |
Why?
|
| Body Weight | 1 | 2013 | 999 | 0.080 |
Why?
|
| Gene Expression | 1 | 2013 | 1569 | 0.080 |
Why?
|
| Tissue Adhesions | 1 | 2008 | 29 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2014 | 12087 | 0.080 |
Why?
|
| Mycoplasma Infections | 1 | 2008 | 8 | 0.080 |
Why?
|
| Ureaplasma Infections | 1 | 2008 | 7 | 0.080 |
Why?
|
| Rubella | 1 | 2008 | 21 | 0.070 |
Why?
|
| Postmenopause | 1 | 2008 | 124 | 0.070 |
Why?
|
| Gonorrhea | 1 | 2008 | 37 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2008 | 252 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1294 | 0.070 |
Why?
|
| Chlamydia Infections | 1 | 2008 | 46 | 0.070 |
Why?
|
| Gonadotropins | 1 | 2007 | 36 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2012 | 1166 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2011 | 449 | 0.070 |
Why?
|
| Cell Size | 1 | 2007 | 81 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2024 | 4507 | 0.070 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 154 | 0.070 |
Why?
|
| Cell Count | 1 | 2007 | 248 | 0.070 |
Why?
|
| Gene Dosage | 1 | 2008 | 441 | 0.070 |
Why?
|
| Age Factors | 1 | 2013 | 2801 | 0.070 |
Why?
|
| Placentation | 1 | 2006 | 53 | 0.070 |
Why?
|
| Maternal Age | 1 | 2005 | 136 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2005 | 338 | 0.060 |
Why?
|
| Recurrence | 1 | 2008 | 1419 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 587 | 0.060 |
Why?
|
| Umbilical Veins | 1 | 2004 | 71 | 0.060 |
Why?
|
| Hematocrit | 1 | 2004 | 110 | 0.060 |
Why?
|
| Pre-Eclampsia | 1 | 2006 | 222 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2013 | 3325 | 0.050 |
Why?
|
| Live Birth | 1 | 2023 | 54 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2005 | 185 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2024 | 133 | 0.050 |
Why?
|
| Vena Cava, Inferior | 1 | 2004 | 100 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2024 | 200 | 0.050 |
Why?
|
| Coronary Circulation | 1 | 2004 | 209 | 0.050 |
Why?
|
| Parvovirus B19, Human | 1 | 2002 | 30 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2023 | 112 | 0.050 |
Why?
|
| Parvoviridae Infections | 1 | 2002 | 36 | 0.050 |
Why?
|
| Ribosomal Proteins | 1 | 2023 | 73 | 0.050 |
Why?
|
| Child | 2 | 2013 | 24144 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2008 | 3050 | 0.050 |
Why?
|
| Fetal Hemoglobin | 1 | 2002 | 28 | 0.050 |
Why?
|
| Rh Isoimmunization | 2 | 2000 | 28 | 0.050 |
Why?
|
| Retreatment | 1 | 2001 | 88 | 0.050 |
Why?
|
| Cell Survival | 1 | 2024 | 803 | 0.050 |
Why?
|
| Male | 4 | 2018 | 59901 | 0.050 |
Why?
|
| Cerebral Arteries | 1 | 2002 | 78 | 0.050 |
Why?
|
| Infant, Newborn | 3 | 2011 | 8070 | 0.050 |
Why?
|
| Embryonic Development | 1 | 2023 | 208 | 0.050 |
Why?
|
| Pulmonary Circulation | 1 | 2002 | 121 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 2105 | 0.040 |
Why?
|
| Middle Aged | 3 | 2008 | 25931 | 0.040 |
Why?
|
| Mothers | 1 | 2023 | 349 | 0.040 |
Why?
|
| Diseases in Twins | 1 | 2000 | 93 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2002 | 753 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2020 | 203 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2002 | 1313 | 0.040 |
Why?
|
| Hemorheology | 1 | 1998 | 28 | 0.040 |
Why?
|
| Pulmonary Artery | 1 | 2002 | 439 | 0.040 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 1998 | 51 | 0.040 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2002 | 443 | 0.040 |
Why?
|
| Pregnancy in Diabetics | 1 | 1997 | 24 | 0.040 |
Why?
|
| Liver | 1 | 2004 | 1727 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 1997 | 218 | 0.030 |
Why?
|
| Insulin | 1 | 2020 | 1197 | 0.030 |
Why?
|
| Time Factors | 2 | 2001 | 6198 | 0.030 |
Why?
|
| Blood Pressure | 1 | 1998 | 1314 | 0.030 |
Why?
|
| Cordocentesis | 2 | 2002 | 10 | 0.020 |
Why?
|
| Hemoglobins | 2 | 2002 | 300 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1997 | 791 | 0.020 |
Why?
|
| Drainage | 2 | 2001 | 254 | 0.020 |
Why?
|
| Amniocentesis | 2 | 1998 | 76 | 0.020 |
Why?
|
| Ureaplasma urealyticum | 1 | 2008 | 1 | 0.020 |
Why?
|
| Mycoplasma hominis | 1 | 2008 | 3 | 0.020 |
Why?
|
| Chlamydia trachomatis | 1 | 2008 | 22 | 0.020 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2008 | 13 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2002 | 2848 | 0.010 |
Why?
|
| Hydrops Fetalis | 1 | 2002 | 75 | 0.010 |
Why?
|
| Pregnancy, High-Risk | 1 | 2002 | 46 | 0.010 |
Why?
|
| Amnion | 1 | 2001 | 38 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 2394 | 0.010 |
Why?
|
| Medical Records | 1 | 2002 | 189 | 0.010 |
Why?
|
| International Cooperation | 1 | 2001 | 160 | 0.010 |
Why?
|
| Encephalomalacia | 1 | 2000 | 4 | 0.010 |
Why?
|
| Morbidity | 1 | 2001 | 240 | 0.010 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2000 | 29 | 0.010 |
Why?
|
| Fetal Death | 1 | 2000 | 113 | 0.010 |
Why?
|
| Blood Group Incompatibility | 1 | 2000 | 27 | 0.010 |
Why?
|
| Isoantibodies | 1 | 2000 | 70 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2000 | 206 | 0.010 |
Why?
|
| Cerebral Palsy | 1 | 2000 | 79 | 0.010 |
Why?
|
| Pregnancy Trimesters | 1 | 1998 | 33 | 0.010 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1998 | 108 | 0.010 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1998 | 158 | 0.010 |
Why?
|
| Diastole | 1 | 1998 | 171 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2001 | 1470 | 0.010 |
Why?
|
| Hexosamines | 1 | 1997 | 17 | 0.010 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 1998 | 93 | 0.010 |
Why?
|
| Birth Weight | 1 | 1998 | 336 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 1998 | 269 | 0.010 |
Why?
|
| Registries | 1 | 2001 | 1382 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 2000 | 1801 | 0.000 |
Why?
|